

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of

**CERTAIN SELECTIVE THYROID
HORMONE RECEPTOR-BETA AGONISTS,
PROCESSES FOR MANUFACTURING OR
RELATING TO SAME, AND PRODUCTS
CONTAINING SAME**

Investigation No. 337-TA-1352

**NOTICE OF COMMISSION DECISION NOT TO REVIEW
AN INITIAL DETERMINATION EXTENDING THE TARGET DATE**

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (the “Commission”) has determined not to review an initial determination (“ID”) (Order No. 59) of the presiding Chief Administrative Law Judge (“Chief ALJ”) extending the target date for completion of the investigation until January 13, 2025.

FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708-4716. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket system (“EDIS”) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 9, 2023, based on a complaint, as supplemented, filed on behalf of Viking Therapeutics, Inc. of San Diego, California. *See* 88 FR 8455-57 (Feb. 9, 2023). The complaint alleges a violation of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, by way of the importation into the United States or in the sale of certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry or prevent the establishment of a domestic industry. *Id.* at 8455-56. The notice of investigation named the following as respondents: Ascletris Pharma Inc. of Hangzhou, Zhejiang Province, China; Ascletris Pharmaceuticals Co. Ltd. of Shaoxing, Zhejiang Province, China; Ascletris Bioscience Co., Ltd. of Hangzhou, Zhejiang Province, China;

Gannex Pharma Co., Ltd. of Shanghai, China; and Jinzi Jason Wu of Seattle, Washington. *Id.* at 8456. The Office of Unfair Import Investigation is also participating in this investigation. *Id.*

On September 22, 2023, the Commission granted a motion to intervene filed by Foster, Murphy, Altman & Nickel, PC. *See* Order No. 37 (Aug. 28, 2023), *unreviewed by* Comm'n Notice (Sept. 22, 2023).

On September 6, 2024, the Chief ALJ issued the subject ID (Order No. 59) extending the target date for completion of the investigation until January 13, 2025. The ID explains that the extension is necessary in view of the complexity of the issues raised in this investigation and current constraints on judicial resources. *See* ID at 1. The ID also states that the deadline for issuing the final ID is September 13, 2024. *See id.*

No party filed a petition for review.

The Commission has determined not to review the subject ID. The target date for completion of the investigation is extended until January 13, 2025.

The Commission's vote for this determination took place on October 7, 2024.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

A handwritten signature in black ink, appearing to read 'Lisa R. Barton', written in a cursive style.

Lisa R. Barton
Secretary to the Commission

Issued: October 7, 2024